Merck of Germany's Hunt For MS BTKi Partner Boosted By Evobrutinib Data

 
• By Sten Stovall

German Merck tells Scrip its quest to find a partner for its Bruton’s tyrosine kinase inhibitor evobrutinib should be helped by positive 24-week Phase IIb data in relapsing multiple sclerosis.

nerve cells, concept for neurodegenerative and neurological disease
Merck KGaA Says Latest Strong Evobrutinib MS Data Will Help With Partnering Its BTKi • Source: Shutterstock

More from Clinical Trials

More from R&D